ASH 2022 roundup: IDH inhibitors

Here, we summarize safety and efficacy data for enasidenib and ivosidenib and the association between IDH mutations in patients with AML and relapse rates after...

Addition of gemtuzumab ozogamicin to induction chemotherapy

We summarize several presentations from ASH 2022 on the impact of gemtuzumab ozogamicin plus chemotherapy and fractionated versus single...

Survival outcomes and treatment response in patients with CBF-AML

We summarize presentations from ASH 2022 and SOHO 2022 investigating the treatment of patients with core-binding factor AML with HDAC...

Inhibition of the menin-KMT2A interaction in AML: The AUGMENT-101 and KOMET-001 trials

The AML Hub summarizes findings from the phase I AUGMENT-001 trial of revumenib for R/R AML and the phase I/II...

EP0042 granted orphan drug designation for the treatment of AML

Following U.S. FDA approval of an investigational new drug application, EP0042, a dual FLT3 and Aurora kinase inhibitor, has been...

ASH 2022 roundup: IDH inhibitors

Here, we summarize safety and efficacy data for enasidenib and ivosidenib and the association between IDH mutations in patients with AML and relapse rates after...

Inhibition of the menin-KMT2A interaction in AML: The AUGMENT-101 and KOMET-001 trials

The AML Hub summarizes findings from the phase I AUGMENT-001 trial of revumenib for R/R AML and the phase I/II...

Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML

We present a visual abstract representing key data from a phase I/II trial investigating the triplet...

Orca-T in patients undergoing allo-HSCT for hematologic malignancies

In this article, we report recent data from two trials on Orca-T in the treatment of patients with hematologic malignancies, both...

Latest insights on TP53 mutations in AML and MDS from ASH 2022

In this article, we summarize several presentations from the 64th ASH Annual Meeting and Exposition on TP53mut and the impact on survival...

Editorial theme | Transplant outcomes across AML mutational subgroups

The AML Hub summarizes two studies evaluating the impact of isocitrate dehydrogenase and secondary-type mutations on allo-HSCT, in...

Briquilimab granted orphan drug designation by the European Commission

On January 4, 2023, briquilimab, a monoclonal antibody targeting the CD117 receptor, was granted orphan drug designation by the...

Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML

Lübbert et al. investigated the efficacy and safety of a 10-day decitabine regimen compared to...

Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors

During the European Hematology Association (EHA) 2022 Congress, the triplet...

Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?

Ossenkoppele begins by introducing the study presented at the congress, outlining the study design...

The QuANTUM-First trial

During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First...